The Indian pharmaceutical landscape is witnessing a major disruption with the patent expiry of Semaglutide (GLP-1 receptor agonist) in March 2026
Life Sci., 54: 1316-1329 Cordido et al (1993), Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity
Because just very empirically, giving someone this coenzyme, this vitamin B3 derivative, how is it dramatically changing symptomatically how someone feels
And lets not forget smoking, since that really impacts risks too
Apply 2-3 drops of serum to your face and neck
For many, the GLP-1 journey involves experimentation: adjusting doses, changing drugs, or moving between branded and compounded options in search of something tolerable